Study Notes on Diagnosis and Treatment of Pulmonary Embolism
Diagnosis of Pulmonary Embolism (PE)
Diagnosing clinical signs of PE is complex and can be mistaken for other conditions.
Key strategy: Assessing risk factors.
Wells Criteria
Developed as a scoring system to determine the likelihood of a patient having PE.
It is a modified version known as Wells Criteria IIA.
Each factor contributes a defined score:
Deep Vein Thrombosis (DVT) Symptoms: +3 points
Alternative diagnosis less likely than PE: +3 points
Heart Rate > 100 bpm: +1.5 points
Immobilization for more than 3 days or surgery within the last 4 weeks: +1.5 points
Previous DVT: +1.5 points
Hemoptysis: +1 point
Malignancy: +1 point
To interpret the total score:
Score > 4: PE is likely
Score ≤ 4: PE is unlikely
Diagnosis Algorithm
After determining likelihood of PE:
If PE is unlikely: Conduct a D-dimer assay.
Possible outcomes: Positive or Negative
Negative D-dimer: No PE; no treatment needed.
Positive D-dimer: Further investigate using a CT pulmonary angiogram.
If PE is likely: Proceed directly to a CT pulmonary angiogram.
Outcomes after CT scan: Negative, Positive, or Unsure.
Negative: No PE; no treatment needed.
Positive: PE confirmed; begin treatment.
Unsure: Additional tests such as ventilation-perfusion scanning may be required.
Positive result: Can rule in PE.
Negative result: Unlikely PE; no treatment needed.
Diagnostic Tools
D-dimer Assay
A crucial part of ruling out PE.
Measures fibrin degradation products in the blood which reveal coagulation activity.
Elevated levels indicate active clot formation in the body.
Coagulation Mechanism
Fibrinogen to Fibrin:
Fibrinogen (yellow structure) becomes fibrin in the presence of thrombin (clotting Factor 2A).
D segments facilitate cross-linking in fibrin mesh.
Plasmin breaks down fibrin, thus facilitating D-dimer measurement.
Treatment of Pulmonary Embolism
Treatment divided into three essential components:
1. General Treatment Actions
Oxygen therapy: Administer for hypoxemia.
Fluid administration: In case of circulatory shock.
Avoid: Diuretics and vasodilators as they decrease cardiac output, which may already be compromised in PE patients.
Pain management can involve opioids, but with caution due to potential hypotensive effects.
2. Anticoagulants
Objective: To prevent the formation of new blood clots.
Minimum treatment duration: 3 months.
Two main classes of anticoagulants:
Heparin (Unfractionated and Low Molecular Weight Heparin [LMWH]):
Intravenous administration for unfractionated heparin.
Subcutaneous administration for LMWH.
Inhibits clotting Factors X and thrombin, leading to reduced fibrin mesh formation.
Warfarin:
Oral dosage that takes effect over approximately 5 days.
Acts as a vitamin K antagonist affecting synthesis of clotting factors II, VII, IX, and X.
Monitoring: Check INR levels to assess anticoagulation effect.
INR range for safety:
Continue warfarin as long as INR is between 2 and 3.
3. Thrombolytic Therapy
Purpose: To actively break down existing clots.
Indicated for acute massive PE and cases of shock.
This therapy focuses on fibrinolysis rather than prevention of new clots.
Monitoring Coagulation Activity
Various tests used to gauge coagulation ability:
Prothrombin Time (PT): Monitors extrinsic pathway and common pathway factors; can also assess liver function.
International Normalized Ratio (INR): Standardized measure to monitor warfarin; elevated INR indicates increased bleeding risk.
Activated Partial Thromboplastin Time (aPTT): Useful for managing heparin therapy; monitors intrinsic pathway and common pathway.
Bleeding Time: Measures time taken for bleeding to stop; normal range is <10 minutes.
Summary of Key Points
Diagnosing PE involves assessing risk factors and utilizing the Wells Criteria.
D-dimer assays and CT pulmonary angiograms play a crucial role in diagnosis.
Treatment protocols include oxygenation, antithrombotic therapies, and thrombolytics.
Continuous monitoring of coagulation through various blood tests ensures patient safety and effective management.